The Anticancer Mechanism of the Ribonucleotide Reductase Inhibiting Drug COH29 Involves Suppression of DNA Repair

  • Bingsen Zhou (Contributor)
  • Keqiang Zhang (Contributor)
  • F. Un (Contributor)
  • Shuya Hu (Contributor)
  • Jun Wu (Contributor)
  • Yan Wang (Contributor)
  • Xiyong Liu (Contributor)
  • Hongzhi Li (Contributor)
  • Zheng Liu (Contributor)
  • Leila Su (Contributor)
  • Yun Yen (Contributor)



Mechanism of Action Study for COH29 Compare COH29 treatment in DNA-repair deficient cell line with truncated BRCA1 (HCC1937) versus phenotypically normal cell line with exogenous WT BRCA1 expression (HCC1937+BRCA1)
Date made available2015

Cite this